Inflammatory Myofibroblastic Tumor: A Multi‐Institutional Study from the Pediatric Surgical Oncology Research Collaborative
Barrie S. Rich,Joanna Fishbein,Timothy Lautz,Nathan S. Rubalcava,Tanvi Kartal,Erika Newman,Pei En Wok,Rodrigo L. P. Romao,Richard Whitlock,Bindi Naik‐Mathuria,Stephanie F. Polites,Katrine Løfberg,Danny Lascano,Eugene Kim,Jacob Davidson,Andreana Bütter,Zachary J. Kastenberg,Scott S. Short,Rebecka L. Meyers,Rosemarie Mastropolo,Marcus M. Malek,Jennine Weller,Ahmer Irfan,Daniel S. Rhee,Alan F. Utria,David H. Rothstein,Kimberly Riehle,Sarah Jane Commander,Elisabeth Tracy,Kerri Becktell,Brian Hallis,Dave Lal,Orville Li,Dorothé B. Dal‐Soglio,Nelson Piché,Oswaldo Gomez Quevedo,Andrew J. Murphy,Andrew M. Davidoff,Jo Cooke Barber,Erin Watters,Roshni Dasgupta,Richard D. Glick,Rodrigo LP Romao,Zachary J Kastenberg
DOI: https://doi.org/10.1002/ijc.34132
2022-05-26
International Journal of Cancer
Abstract:Inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm of intermediate malignancy. We describe the largest cohort of IMT patients to date, aiming to further characterize this rare, poorly understood tumor. This is a multi‐institutional review of IMT patients ≤39 years, from 2000‐2018, at 18 hospitals in the Pediatric Surgical Oncology Research Collaborative. 182 patients were identified with median age of 11 years. 33% of tumors were thoracic in origin. Presenting signs/symptoms included pain (29%), respiratory symptoms (25%), and constitutional symptoms (20%). Median tumor size was 3.9 cm. Anaplastic lymphoma kinase (ALK) overexpression was identified in 53% of patients. 7% of patients had distant disease at diagnosis. 91% of patients underwent resection: 14% received neoadjuvant treatment and 22% adjuvant treatment. 12% of patients received an ALK inhibitor. 66% of surgical patients had complete resection, with 20% positive microscopic margins, and 14% gross residual disease. Approximately 40% had en bloc resection of involved organs. Median follow‐up time was 36 months. Overall 5‐year survival (OS) was 95% and 5‐year event‐free survival (EFS) was 80%. Predictors of recurrence included respiratory symptoms, tumor size, and distant disease. Gross or microscopic margins were not associated with recurrence, suggesting that aggressive attempts at resection may not be warranted. This article is protected by copyright. All rights reserved.
oncology